# Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

> **NCT07468916** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Atypical Chronic Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified
- Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Ropeginterferon Alfa-2B

## Key facts

- **NCT ID:** NCT07468916
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-29
- **Primary completion:** 2031-09-30
- **Final completion:** 2032-09-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468916, "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07468916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*